Abstract

Over 80% of cancer patients are treated in the community. In recognition of this, the faculty of the Oncology Research Center (ORC) of Bowman Gray School of Medicine organized an outreach program in 1976 in order to allow community physicians the opportunity of participating in trials of the latest advances in cancer therapy. The ORC's original 1983 application as a CCOP Research Base was developed to strengthen the participation of community physicians in clinical trials. ORC faculty also believed that the educational benefits of community physician involvement in clinical research would benefit those patient not directly treated on research protocols. The ORC's ten year history of conducting clinical trials with community physicians has demonstrated its ability to develop appropriate studies, act as a coordinating and data management center, establish quality control measures, analyze and publish the results, train community data personnel, and organize quarterly scientific and educational meetings. It has shown its ability to develop high quality treatment protocols and its interest in cancer control protocols. With an expanded number of CCOP applicants, projected increase of patient enrollment, and its new initiatives in cancer control, the ORC expects to continue its contributions to cancer research.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA037378-04
Application #
3557990
Study Section
(SRC)
Project Start
1983-09-15
Project End
1990-05-31
Budget Start
1987-08-28
Budget End
1988-05-31
Support Year
4
Fiscal Year
1987
Total Cost
Indirect Cost

  Institution

Name
Wake Forest University Health Sciences
Department
Type
Schools of Medicine
DUNS #
041418799
City
Winston-Salem
State
NC
Country
United States
Zip Code
27106

  Publications

Atkins, J N; Muss, H B; Case, L D et al. (1996) Leucovorin and high-dose fluorouracil in metastatic prostate cancer. A phase II trial of the piedmont Oncology Association. Am J Clin Oncol 19:23-5
Thomas, G W; Muss, H B; Jackson, D V et al. (1994) Vincristine with high-dose etoposide in advanced breast cancer: a phase II trial of the Piedmont Oncology Association. Cancer Chemother Pharmacol 35:165-8
Muss, H B; Case, L D; Atkins, J N et al. (1994) Tamoxifen versus high-dose oral medroxyprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: a Piedmont Oncology Association study. J Clin Oncol 12:1630-8
Christman, K; Muss, H B; Case, L D et al. (1992) Chemotherapy of metastatic breast cancer in the elderly. The Piedmont Oncology Association experience [see comment] JAMA 268:57-62
Cruz, J M; Muss, H B; Russell, G (1992) High-dose megestrol acetate as third-line endocrine therapy for metastatic breast cancer. Oncology 49 Suppl 2:8-11
Schifeling, D J; Jackson, D V; Zekan, P J et al. (1992) Fluoxymesterone as third line endocrine therapy for advanced breast cancer. A phase II trial of the Piedmont Oncology Association. Am J Clin Oncol 15:233-5
Davis, M; Williford, S; Muss, H B et al. (1992) A phase I-II study of recombinant intrapleural alpha interferon in malignant pleural effusions. Am J Clin Oncol 15:328-30
Atkins, J N; Muss, H B; Case, D et al. (1991) High-dose 24-hour infusion of 5-fluorouracil in metastatic prostate cancer. A phase II trial of the Piedmont Oncology Association. Am J Clin Oncol 14:526-9
Muss, H B; Case, L D; Richards 2nd, F et al. (1991) Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association. N Engl J Med 325:1342-8
Muss, H B; Tell, G S; Case, L D et al. (1991) Perceptions of follow-up care in women with breast cancer. Am J Clin Oncol 14:55-9

Showing the most recent 10 out of 14 publications